IL-24 contributes to skin inflammation in Para-Phenylenediamine-induced contact hypersensitivity.
Adult
Aged
Animals
Biopsy
Coloring Agents
Cytokines
/ metabolism
Dermatitis, Allergic Contact
/ metabolism
Disease Models, Animal
Humans
Immunoglobulin E
/ metabolism
Inflammation
/ chemically induced
Interleukins
/ metabolism
Leukocyte Common Antigens
/ metabolism
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Middle Aged
Phenylenediamines
Receptors, Interleukin
/ metabolism
Skin
/ drug effects
Interleukin-22
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 02 2019
12 02 2019
Historique:
received:
28
06
2018
accepted:
19
12
2018
entrez:
14
2
2019
pubmed:
14
2
2019
medline:
24
9
2020
Statut:
epublish
Résumé
Para-Phenylenediamine (PPD) is an aromatic amine used in hair dyes and in temporary black henna tattoos, which is a frequent cause of allergic contact dermatitis (ACD). ACD is a skin inflammatory reaction characterized by modifications such as spongiosis, exocytosis and acanthosis. The aim of this study is to characterize the expression and the role of IL-20-related cytokines, including IL-19, IL-20, IL-22 and IL-24, in ACD. The expression of IL19, IL20, IL22 and IL24 is increased in affected skin from PPD allergic patients compared with uninvolved skin. In addition, the expression of these cytokines positively correlates with clinical symptoms. To assess their role in ACD, we set up a mouse model of PPD-induced allergic contact dermatitis and we showed that, in contrast to Il22-deficient mice, Il22ra1-, Il20rb- and Il24-deficient mice are partially protected against development of PPD-induced contact hypersensitivity. These mice have decreased ear thickening and less acanthosis compared with WT mice after PPD treatment. In addition, the absence of IL-22R, IL-20R2 or IL-24 affects the recruitment of neutrophils into the skin but not the total IgE production. Taken together, these results demonstrate the implication of IL-24 via the IL-20R type II receptor in the inflammatory process of ACD.
Identifiants
pubmed: 30755657
doi: 10.1038/s41598-018-38156-4
pii: 10.1038/s41598-018-38156-4
pmc: PMC6372603
doi:
Substances chimiques
Coloring Agents
0
Cytokines
0
Il24 protein, mouse
0
Interleukins
0
Phenylenediamines
0
Receptors, Interleukin
0
interleukin-20 receptor
0
interleukin-22 receptor
0
interleukin-24
0
Immunoglobulin E
37341-29-0
Leukocyte Common Antigens
EC 3.1.3.48
4-phenylenediamine
U770QIT64J
interleukin 20
U91R7IMG8U
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1852Références
Contact Dermatitis. 1999 Dec;41(6):348-9
pubmed: 10617223
Cell. 2001 Jan 12;104(1):9-19
pubmed: 11163236
J Immunol. 2001 Oct 1;167(7):3545-9
pubmed: 11564763
J Biol Chem. 2002 Dec 6;277(49):47517-23
pubmed: 12351624
Immunity. 2002 Sep;17(3):375-87
pubmed: 12354389
Clin Dermatol. 2003 Mar-Apr;21(2):95-100
pubmed: 12706326
Clin Exp Immunol. 2003 Jun;132(3):385-92
pubmed: 12780683
J Immunol. 2004 Dec 1;173(11):6712-8
pubmed: 15557163
Exp Dermatol. 2006 Dec;15(12):991-1004
pubmed: 17083366
Contact Dermatitis. 2007 Jan;56(1):56-7
pubmed: 17177720
J Immunol. 2007 Feb 15;178(4):2229-40
pubmed: 17277128
Clin Exp Immunol. 2007 Dec;150(3):407-15
pubmed: 17900301
J Immunol. 2007 Dec 15;179(12):8098-104
pubmed: 18056351
J Allergy Clin Immunol. 2009 Feb;123(2):486-92
pubmed: 18986691
Contact Dermatitis. 2008 Dec;59(6):327-43
pubmed: 19076884
J Immunol. 2009 Jan 15;182(2):802-10
pubmed: 19124723
Contact Dermatitis. 2009 Jan;60(1):57-8
pubmed: 19125725
J Mol Med (Berl). 2009 May;87(5):523-36
pubmed: 19330474
J Immunol. 2009 Jul 15;183(2):1463-70
pubmed: 19553527
Br J Dermatol. 2010 Jan;162(1):102-7
pubmed: 19785606
J Immunol. 2010 Feb 15;184(4):1793-8
pubmed: 20061404
Immunopharmacol Immunotoxicol. 2010 Dec;32(4):700-4
pubmed: 20235740
Annu Rev Immunol. 2011;29:71-109
pubmed: 21166540
J Immunotoxicol. 2011 Jan-Mar;8(1):46-55
pubmed: 21299354
J Immunol. 2011 Apr 1;186(7):4098-109
pubmed: 21357535
Immunity. 2011 Oct 28;35(4):596-610
pubmed: 21982596
J Immunol. 2012 Jan 1;188(1):462-9
pubmed: 22131335
APMIS. 2012 Jan;120(1):1-27
pubmed: 22151305
Nat Rev Immunol. 2012 Jan 13;12(2):114-24
pubmed: 22240625
Adv Skin Wound Care. 2012 Aug;25(8):371-80; quiz 381-2
pubmed: 22820963
J Invest Dermatol. 2013 Feb;133(2):303-15
pubmed: 22931926
Contact Dermatitis. 2013 Jun;68(6):339-47
pubmed: 23692034
Allergy. 2014 Jan;69(1):125-31
pubmed: 24372156
J Invest Dermatol. 2014 Nov;134(11):2757-2767
pubmed: 25046339
Clin Exp Dermatol. 2014 Dec;39(8):924-31
pubmed: 25196929
Nat Rev Immunol. 2014 Dec;14(12):783-95
pubmed: 25421700
J Exp Med. 2015 Jan 12;212(1):15-22
pubmed: 25512469
J Invest Dermatol. 2016 Feb;136(2):409-415
pubmed: 26802237
J Invest Dermatol. 2017 May;137(5):1094-1103
pubmed: 28115058
Clin Exp Immunol. 2017 Sep;189(3):342-351
pubmed: 28369789
PLoS One. 2017 Apr 20;12(4):e0175802
pubmed: 28426699
Contact Dermatitis. 2017 Jul;77(1):1-16
pubmed: 28497472
J Allergy Clin Immunol. 2018 Jan;141(1):152-162
pubmed: 28583370
Curr Allergy Asthma Rep. 2017 Nov 11;17(12):83
pubmed: 29129023
J Immunol. 1997 Sep 1;159(5):2484-91
pubmed: 9278342